BC
RGLS

Broadfin Capital’s Regulus Therapeutics RGLS Stock Holding History

Broadfin Capital’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-12,578
Closed -$1.57M – 54
2017
Q4 		$1.57M Sell
12,578
-23,210
-65% -$2.94M 0.26% 38
2017
Q3 		$5.37M Buy
+35,788
New +$4.5M 0.79% 32

Other funds holding RGLS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SDIC
South Dakota Investment Council Sioux Falls, South Dakota $5.24B AUM 22.1% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AC
Ascend Capital Orinda, California $1.99B AUM 10.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Broadfin Capital's RGLS Position: Q1 2018 in Review

Broadfin Capital sold out of Regulus Therapeutics (RGLS) in Q1 2018, closing a stake of 12,578 shares — an estimated $1.57M sold.

Broadfin Capital first reported a position in RGLS in Q3 2017 and held it in 2 quarters. The position peaked at $5.37M in Q3 2017. 50 funds tracked by Wall St. Rank hold RGLS as of Q1 2018.

  • Broadfin Capital reported no remaining Regulus Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Broadfin Capital sold 12,578 Regulus Therapeutics shares in Q1 2018, an estimated $1.57M.
  • Broadfin Capital first reported a position in Regulus Therapeutics in Q3 2017 and held it in 2 quarters.
  • Broadfin Capital's Regulus Therapeutics position peaked at $5.37M in Q3 2017.
  • 50 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q1 2018.

Based on Broadfin Capital's 13F filing for Q1 2018, filed 14 May 2018.